Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Value Concentration

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Feb 27, 2022 1:09pm

121 Views

Post# 34465770

RE:RE:RE:Value Concentration

Let's worry about money if we ever need to go in search of it again.

Right now, let's get 346 and 352 to P2.
By then we'll also know where we stand on the chronic side and what's needed next.

Also remember, summer is a world away when it comes to drug development companies - too early to tell where we'll be by then.

Good Luck Longs !!!!

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December